



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Credelio 112 mg Chewable Tablets for Dogs (>2.5–5.5 kg)

Vm 52127/5004

• 06 January 2025	Addition of additional adverse events to Credelio Chewable Tablets for Dogs: Pruritus, Haemorrhagic diarrhoea, Urinary incontinence, Inappropriate urination, Polyuria/ pollakiuria and Polydipsia (and editorial changes to maintain alignment).
• 13 March 2024	Introduction of a new 18 tablet pack size presentation.
• 13 March 2024	Change in shape and dimensions of the immediate packaging of a non-sterile finished product.
• 29 September 2023	One-off alignment of the product information with version 9.0* of the QRD templates.
• 11 October 2022	Change in batch size of the active substance.
• 30 September 2022	New indication: for the treatment of demodicosis.
• 14 July 2022	Renewal.
• 01 December 2021	Changes in the manufacturing process of the active substance.
• 16 April 2021	Change in control of excipient of finished product – variation to extend shelf-life of the excipient meat dry flavour.